ALZ 101
Alternative Names: ALZ-101Latest Information Update: 27 Sep 2024
At a glance
- Originator Alzinova
- Class Alzheimer vaccines
- Mechanism of Action Amyloid beta-protein modulators; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 28 Jul 2024 Immunogenicity and adverse events data from a phase I trial in Alzheimer's disease presented at the Alzheimer's Association International Conference 2024 (AAIC-2024)
- 29 Oct 2021 Phase-I clinical trials in Alzheimer's disease in Finland (IM, Injection) (NCT05328115) (EudraCT-2019-002277-62)
- 30 Sep 2021 Alzinova receives regulatory authority approval in Finland to initiate phase Ib trial in Alzheimer's disease